Table 7.
Efficacy of 400 mg sofosbuvir QD + ribavirin for 24 weeks.
| Cirrhosis | Prior treatment | SVR12 rate |
Study and trial phase | Ref. | |||
|---|---|---|---|---|---|---|---|
| GT-1 | GT-2 | GT-3 | GT-4 | ||||
| No cirrhosis |
Experienced | 1a: 80% (8/10), 1b: 50% (3/6) | 100% (5/5) | 0% (0/1) | Phase 2 | Charlton et al., 2015a | |
| Naïve | 100% (11/11) | Phase 2 | Ruane et al., 2015 | ||||
| Experienced | 81.8% (9/11) | ||||||
| Naïve | ? | SPARE, phase 2 | Osinusi et al., 2013 | ||||
| Naïve | 90.4% (141/156) | ASTRAL-2, ASTRAL-3, phase 3 |
Foster et al., 2015b | ||||
| Experienced | 70.9% (22/31) | ||||||
| Naïve | 94.6% (87/92) | VALENCE, phase 3 | Zeuzem et al., 2014a | ||||
| Experienced | 86.7% (85/98) | ||||||
| Naïve | 90.3% (65/72) | BOSON, phase 3 | Foster et al., 2015a | ||||
| Experienced | 81.5% (44/54) | ||||||
| Naïve | 90.5% (19/21) | Real-world study | Doss et al., 2015 | ||||
| Experienced | 95.2% (20/21) | ||||||
| Naïve or experienced | 75% (3/4) | 76.9% (10/13) | Real-world study | Maasoumy et al., 2016 | |||
| Cirrhosis | Experienced | 1a: 66.7% (8/12), 1b: 50% (2/4) | 100% (1/1) | Phase 2 | Charlton et al., 2015a | ||
| Naïve | 100% (3/3) | Phase 2 | Ruane et al., 2015 | ||||
| Experienced | 100% (4/4) | ||||||
| Naïve | ? | SPARE, phase 2 | Osinusi et al., 2013 | ||||
| Naïve | 73.3% (33/45) | ASTRAL-2, ASTRAL-3, phase 3 |
Foster et al., 2015b | ||||
| Experienced | 57.9% (22/38) | ||||||
| Naïve | 92.3% (12/13) | VALENCE, phase 3 | Zeuzem et al., 2014a | ||||
| Experienced | 61.7% (29/47) | ||||||
| Naïve | 81.8% (18/22) | BOSON, phase 3 | Foster et al., 2015a | ||||
| Experienced | 100% (17/17) | 76.5% (26/34) | |||||
| Naïve | 100% (3/3) | Egyptian study | Doss et al., 2015 | ||||
| Experienced | 66.7% (4/6) | ||||||
| Naïve or experienced | 48.1% (13/27) | 52.6% (10/19) | Real-world study | Maasoumy et al., 2016 | |||
?: Question marks indicate that the data was unavailable in literature.